pucotenlimab

Key facts

Mechanism of action

Programmed cell death protein 1 inhibitor

Primary target: Programmed cell death protein 1

Approval history

1. MRG003 combined with Pucotenlimab Phase 2 · Chinese Academy of · Head and Neck Squamous Cell Carcinoma (HNSCC)
2. Pucotenlimab Phase 2 · Sun Yat-sen University · Colorectal Cancer (CRC)
3. Pucotenlimab Phase 2 · Zhejiang Provincial People's · Pancreatic Cancer

1. cemiplimab Antineoplastic and immunomodulating agents (L01)
2. cemiplimab-rwlc Programmed cell death protein 1 inhibitor
3. tislelizumab Antineoplastic and immunomodulating agents (L01)
4. toripalimab-tpzi Programmed cell death protein 1 antagonist
5. dostarlimab-gxly Programmed cell death protein 1 antagonist
6. islelizumab-jsgr Programmed cell death protein 1 inhibitor

Frequently asked questions